Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Aducanumab in Early Alzheimer's Disease
2015-000966-72Phase 3Terminated
- Sponsor
- Biogen
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Aducanumab arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in MMSE score at Week 78. Started Jun 2015; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-000966-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000966-72.